You are here

Article Text

Article menu
Download PDFPDF
Letters
PostScript
Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis
  1. M R Horton,
  2. S K Danoff,
  3. N Lechtzin
  1. Johns Hopkins University School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Baltimore, Maryland, USA
  1. Dr M R Horton, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 500, Baltimore, MD 21212, USA; mhorton2{at}jhem.jhmi.edu

https://doi.org/10.1136/thx.2008.098699

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Idiopathic pulmonary fibrosis (IPF) is a progressive lung disorder of unknown aetiology that leads to death in the majority of patients within 3–5 years of diagnosis.1 One of the most prominent features of IPF is a persistent dry cough that affects 73–86% of patients.1 The aetiology of the cough is unknown but presumably linked to the lung fibrosis. Unfortunately, the cough is often disabling and resistant to traditional antitussive therapies.2

    We present findings from a prospective cohort of 11 individuals with chronic cough caused by IPF who were enrolled in an open label phase II trial of thalidomide. Thalidomide was administered daily in 100–400 mg doses. Patients were followed …

    View Full Text

    Footnotes

    • Funding: The clinical trial in which the subjects of this observational cohort participated was investigator initiated and sponsored. Celgene Corporation was a supporter of the trial and provided monetary support for the trial. The authors have no financial or personal relationship beyond the clinical trial support with Celgene Corporation.

    • Competing interests: None.

    • Ethics approval: Ethics approval was obtained.